New drug tested to fight inflammation in kidney disease patients
NCT ID NCT05379829
Summary
This study tested how the drug ziltivekimab works in the body of Chinese adults who have chronic kidney disease and signs of body-wide inflammation. Twenty-four participants received either the drug or a placebo dummy injection three times over several months. Researchers measured how long the drug stayed in the blood and checked its effect on a key inflammation marker and overall safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE AND SYSTEMIC INFLAMMATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
-
Chinses People's Liberation Army General Hospital-Nephrology
Beijing, Beijing Municipality, 100853, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
The First Affiliated Hospital Of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of Soochow University-Endocrinology
Suzhou, Jiangsu, 215006, China
-
Zhongda Hospital Southeast University-Nephrology
Nanjing, Jiangsu, 210009, China
-
Zhongda Hospital Southeast University-Neurology
Nanjing, Jiangsu, 210009, China
Conditions
Explore the condition pages connected to this study.